These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22239896)

  • 41. Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.
    Fujino Y; Attizzani GF; Bezerra HG; Wang W; Tahara S; Yamamoto H; Chamie D; Kanaya T; Mehanna E; Takagi K; Nakamura S; Costa MA
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1035-45. PubMed ID: 24156964
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optical coherence tomography and intravascular ultrasound imaging of bioabsorbable magnesium stent degradation in porcine coronary arteries.
    Slottow TL; Pakala R; Okabe T; Hellinga D; Lovec RJ; Tio FO; Bui AB; Waksman R
    Cardiovasc Revasc Med; 2008; 9(4):248-54. PubMed ID: 18928950
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study.
    Eshtehardi P; Cook S; Wandel S; Räber L; Wenaweser P; Togni M; Vogel R; Garachemani A; Eberli FR; Lüscher TF; Jüni P; Hess OM; Meier B; Windecker S
    EuroIntervention; 2010 Sep; 6(4):467-74. PubMed ID: 20884434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial.
    Tamburino C; La Manna A; Di Salvo ME; Sacchetta G; Capodanno D; Mehran R; Dangas G; Corcos T; Prati F
    JACC Cardiovasc Interv; 2009 Mar; 2(3):197-204. PubMed ID: 19463426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravascular ultrasound analysis of small vessel lesions treated with the Sparrow coronary stent system: results of the CARE II trial.
    Kume T; Waseda K; Koo BK; Yock PG; Botelho R; Verheye S; Whitbourn R; Meredith I; Worthley S; Hai KT; Honda Y; Abizaid A; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2014 Jan; 83(1):19-24. PubMed ID: 23413202
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preliminary observations using optical coherence tomography to assess neointimal coverage of a metal stent in a porcine model.
    Mills JS; N'diaye CS; Yow E; Urtz M; Povsic TJ; Greenfield JC; Phillips HR
    Cardiovasc Revasc Med; 2009; 10(4):229-35. PubMed ID: 19815170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of left main coronary artery bifurcation lesions treated with biolimus-eluting DEVAX AXXESS plus nitinol self-expanding stent: intravascular ultrasound results of the AXXENT trial.
    Hasegawa T; Ako J; Koo BK; Miyazawa A; Sakurai R; Chang H; Dens J; Verheye S; Grube E; Honda Y; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):34-41. PubMed ID: 19089934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography.
    Souteyrand G; Levesque S; Ouchchane L; Sarry L; Eschalier R; Lusson JR; Motreff P
    Arch Cardiovasc Dis; 2011 Mar; 104(3):147-54. PubMed ID: 21497303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal stent expansion and complete neointimal coverage: does this association make sense?
    Mintz GS; Choi SY
    JACC Cardiovasc Interv; 2009 Oct; 2(10):995-6. PubMed ID: 19850261
    [No Abstract]   [Full Text] [Related]  

  • 50. Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis.
    Dussaillant GR; Mintz GS; Pichard AD; Kent KM; Satler LF; Popma JJ; Wong SC; Leon MB
    J Am Coll Cardiol; 1995 Sep; 26(3):720-4. PubMed ID: 7642865
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent.
    Jabara R; Pendyala L; Geva S; Chen J; Chronos N; Robinson K
    EuroIntervention; 2009 Dec; 5 Suppl F():F58-64. PubMed ID: 22100678
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detailed comparison of intra-stent conditions 12 months after implantation of everolimus-eluting stents in patients with ST-segment elevation myocardial infarction or stable angina pectoris.
    Mizoguchi T; Sawada T; Shinke T; Yamada S; Okamoto H; Kim SS; Takarada A; Yasaka Y
    Int J Cardiol; 2014 Feb; 171(2):224-30. PubMed ID: 24388538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III.
    Miyazawa A; Ako J; Hongo Y; Hur SH; Tsujino I; Courtney BK; Hassan AH; Kandzari DE; Honda Y; Fitzgerald PJ;
    Am Heart J; 2008 Jan; 155(1):108-13. PubMed ID: 18082499
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of reduced-dose sirolimus-eluting stents in the human coronary artery: serial IVUS analysis of neointimal hyperplasia and luminal dimension.
    Nakamura M; Abizaid A; Hirohata A; Honda Y; Sousa JE; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2007 Dec; 70(7):946-51. PubMed ID: 17621671
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serial morphological and functional assessment of drug-eluting balloon for in-stent restenotic lesions: mechanisms of action evaluated with angiography, optical coherence tomography, and fractional flow reserve.
    Agostoni P; Belkacemi A; Voskuil M; Nathoe HM; Doevendans PA; Stella PR
    JACC Cardiovasc Interv; 2013 Jun; 6(6):569-76. PubMed ID: 23683736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Visualization of neointima formation by optical coherence tomography.
    Kume T; Akasaka T; Kawamoto T; Watanabe N; Toyota E; Sukmawan R; Sadahira Y; Yoshida K
    Int Heart J; 2005 Nov; 46(6):1133-6. PubMed ID: 16394609
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: intravascular ultrasound results of the AXXESS PLUS trial.
    Miyazawa A; Ako J; Hassan A; Hasegawa T; Abizaid A; Verheye S; McClean D; Neumann FJ; Grube E; Honda Y; Fitzgerald PJ
    Catheter Cardiovasc Interv; 2007 Dec; 70(7):952-7. PubMed ID: 18044777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravascular ultrasound assessment of neointima distribution and the length of stent that was free of intravascular ultrasound-detectable intimal hyperplasia in paclitaxel-eluting stents.
    Mintz GS; Hong MK; Raizner AE; Lee CW; Kim JJ; Escolar E; Fearnot NE; Park SW; Park SJ; Weissman NJ
    Am J Cardiol; 2005 Jan; 95(1):107-9. PubMed ID: 15619404
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Frequency-domain optical coherence tomography assessment of unprotected left main coronary artery disease-a comparison with intravascular ultrasound.
    Fujino Y; Bezerra HG; Attizzani GF; Wang W; Yamamoto H; Chamié D; Kanaya T; Mehanna E; Tahara S; Nakamura S; Costa MA
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E173-83. PubMed ID: 23359350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.